Human tnfrsf25 antibody

Abstract

Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.

1 - 46 . (canceled) 
     
     
         47 . A method of treating a tumor in a subject, comprising administering to a subject a composition comprising an anti-tumor necrosis factor superfamily receptor 25 (TNFRSF25) antibody, the anti-TNFRSF25 antibody comprising:
 (a) a heavy chain comprising a heavy chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 4, a CDR2 sequence as set forth in SEQ ID NO: 6, and a CDR3 sequence as set forth in SEQ ID NO: 8; and   (b) a light chain comprising alight chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 11, a CDR2 sequence as set forth in SEQ ID NO: 13, and a CDR3 sequence as set forth in SEQ ID NO: 15.   
     
     
         48 . The method of  claim 47 , wherein the heavy chain variable region comprises the amino acid sequence having at least 90% identity to SEQ ID NO: 1. 
     
     
         49 . The method of  claim 47 , wherein the light chain variable region comprises the amino acid sequence having at least 90% identity to SEQ ID NO: 2. 
     
     
         50 . The method of  claim 47 , wherein the heavy constant region of the antibody is selected from human IgG1, IgG2, IgG3, and IgG4. 
     
     
         51 . The method of  claim 50 , wherein the heavy constant region is from human IgG4. 
     
     
         52 . The method of  claim 47 , wherein the method further comprises administering an additional agent for treating cancer. 
     
     
         53 . The method of  claim 52 , wherein the additional agent comprises an agent that targets CTLA-4, PD-1, PD-L1, LAG-3, Tim-3, TNFRSF4, TNFRSF9, TNFRSF18, CD27, CD39, CD47, CD73, or CD278. 
     
     
         54 . The method of  claim 52 , wherein the additional agent comprises a TNF receptor superfamily costimulatory molecule. 
     
     
         55 . The method of  claim 52 , wherein the additional agent comprises chimeric antigen receptor-transfected T cells or expanded tumor infiltrating lymphocytes for use in an adoptive T cell therapy. 
     
     
         56 . The method of  claim 52 , wherein the additional agent comprises a chemotherapeutic agent.